Preclinical evaluation of triple-mutated oncolytic herpes virus expressing fusion-type interleukin 12 for malignant melanoma Authors: Miwako Iwai, Akiko Higuchi Nonaka, Minoru Tanaka, Hiroshi Fukuhara, Tomoki Todo Published: 2026 ABSTRACT AbstractG47Δ, a triple-mutated oncolytic herpes simplex virus type 1 (HSV-1) marketing-approved for malignant glioma, has demonstrated high efficacy including survival benefits via robust oncolytic activities with efficient antitumor immunity induction. G47Δ-based, oncolytic HSV-1 expressing fusion-type interleukin 12 (IL-12), murine (T-mfIL12) and human (T-hIL12), were preclinically evaluated for the treatment of malignant melanoma. In DBA/2 mice harboring syngeneic clone M-3 melanoma, intratumoral T-mfIL12 not only suppressed the tumor growth but also upregulated the immune mediator gene expressions in both the injected and non-injected remote tumors. The efficacy was further enhanced by combined treatment with systemic PD-1 blockade. For clinical translation, safety evaluations were conducted in HSV-1-sensitive A/J mice. The toxicity was primarily tested by injecting T-mfIL12 or T-hIL12 into the brain. Also, after administering the viruses intradermally at high doses, clinical signs, body weight, histopathology, cytokine responses, and viral biodistribution were examined. No significant adverse effects were observed, and viral DNA remained confined to the injection site. Intratumoral T-mfIL12 injection caused a transient increase in the serum IL-12 level, with limited effects on the systemic cytokine/chemokine profiles. Based on these data, an investigator-initiated phase 1/2 clinical trial of T-hIL12 in patients with advanced malignant melanoma is currently underway (jRCT2033190086).Keywords: MT: Regular Issue, oncolytic virus therapy, herpes simplex virus type 1, interleukin 12, malignant melanoma, PD-1 blockade, preclinical safety, G47Δ, T-hIL12, oncolytic immunotherapy Introduction Malignant melanoma is the most aggressive form of skin cancer, characterized by rapid progression, early metastasis, and resistance to conventional therapies. Immune checkpoint inhibitors (ICIs), such as anti-PD-1 antibodies (nivolumab and pembrolizumab) and anti-CTLA-4 antibody (ipilimumab), have markedly improved survival rates in patients with advanced melanoma. However, the high incidence of immune-related adverse events associated with combination regimens often limits their long-term use, highlighting the need for safer, more effective strategies.1 Oncolytic virus therapy is a new immunotherapeutic approach that employs genetically modified viruses to selectively replicate in and kill tumor cells, while eliciting antitumor immunity.2,3,4 Melanoma is considered to be a favorable target because of its immunogenic nature. Several oncolytic viruses, including T-VEC, RP-1, T3011 (HSV-1-based), BT-001 (vaccinia virus), and TILT-123 (adenovirus), are currently undergoing advanced clinical evaluation,5 with T-VEC approved by the FDA and EMA in 2015 for unresectable melanoma.6,7 The aforementioned oncolytic HSV-1 share the common mutation of the γ34.5 deletions, attenuating the pathogenicity, but with (T-VEC and RP-1) or without (T3011) the α47 deletion, the former theoretically resulting in higher intratumoral replication capabilities. G47Δ is a third-generation oncolytic HSV-1 with triple mutations in the γ34.5, ICP6, and α47 genes, realizing enhanced tumor selective viral replication, induction of robust systemic antitumor immunity and high safety features all at the same time.8 G47Δ was approved for marketing in Japan as teserpaturev (Delytact) for the treatment of malignant glioma in 2021.9,10 Based on its safety and efficacy, efforts have been made to arm G47Δ with therapeutic cytokines, including interleukin 12 (IL-12), to further boost antitumor responses. IL-12 is a potent immunostimulatory cytokine that promotes T cell and natural killer cell activation, enhances cytotoxicity, and induces interferon (IFN)-γ production. Although its antitumor potential is well established, systemic IL-12 therapy has caused severe toxicity in clinical trials, such as flu-like symptoms, hypotension, elevations in liver enzymes, and even deaths,11,12 necessitating alternative delivery approaches. Recent reviews highlight advances in IL-12 delivery strategies and their integration into multimodal cancer therapies.13,14,15 Replication-competent HSV-1 vectors, with a large genomic capacity and tumor selectivity, are well suited for localized IL-12 expression. Indeed, several IL-12-expressing oncolytic HSV-1 have shown enhanced efficacy in preclinical cancer models, including glioma, breast cancer, squamous cell carcinoma, and hepatocellular carcinoma.16,17,18,19,20 We previously developed T-mfIL12, a G47Δ-based oncolytic HSV-1 encoding fusion-type murine IL-12, in which the p35 and p40 subunits are linked to a single open reading frame. This design conferred higher expression of functional IL-12 and enhanced antitumor efficacy compared with constructs co-expressing the two separate subunits.21 Based on these findings, we constructed T-hIL12, a clinical candidate expressing fusion-type human IL-12, using the same viral backbone and gene design. The present study was conducted as a preclinical evaluation to justify the initiation of a phase 1/2 clinical trial of T-hIL12 in patients with advanced malignant melanoma (jRCT2033190086). Because the phase 2 was designed to add repeated intratumoral T-hIL12 injections on the standard initial therapy using nivolumab, we comprehensively investigated the therapeutic efficacy of T-mfIL12 in murine melanoma models, including in combination with systemic PD-1 blockade, and assessed the safety of both T-mfIL12 and T-hIL12 in HSV-1-sensitive mice. Results T-mfIL12 exhibits potent oncolytic effects in a mouse melanoma model To evaluate the therapeutic potential of IL-12-expressing oncolytic HSV-1, we first assessed the efficacy of its parental virus G47Δ in melanoma models. Although the cytopathic activities of G47Δ have been shown in some human melanoma cell lines (e.g., 888 and 1102),8 its therapeutic activity against melanoma has not been extensively characterized. In vitro, G47Δ nearly eradicated five different human melanoma cell lines (A2058, Mewo, 624, 888, and 938) at a multiplicity of infection (MOI) of 0.1 by day 4, and substantial cytotoxicity was also observed at an MOI of 0.01 in most cell lines (Figure S1A). The cytopathic effects at MOI of 0.1 were significantly stronger than those at MOI of 0.01 in all cell lines tested (p < 0.001 for all cell lines, two-way ANOVA). In vivo, G47Δ significantly suppressed tumor growth in subcutaneous A2058 and Mewo xenografts in athymic mice following intratumoral injection (A2058, p = 0.0035; Mewo, p = 0.0003; Figure S1B). These results demonstrate that human melanoma cells are highly susceptible to G47Δ, validating its utility as a backbone for the development of IL-12-expressing derivatives. Next, we examined the therapeutic efficacy of T-mfIL12 in an immunocompetent murine melanoma model using Clone M-3 cells derived from DBA/2 mice. T-mfIL12 exhibited cytopathic effects (Figure 1A) and replication efficiency (Figure 1B) comparable to those of G47Δ and the control virus T-01. ELISA confirmed IL-12 expression in T-mfIL12-infected Clone M-3 and Vero cells (Figure 1C). Efficacy of T-mfIL12 against murine melanoma Clone M-3 cells (A) Cytopathic effect of T-mfIL12, G47Δ, and T-01 in vitro. Clone M-3 cells were infected with each virus at an MOI of 0.1 or 1, and viable cells were counted daily using a Coulter counter. Cell viability is expressed as a percentage relative to that of the mock-infected controls. The results are presented as the mean ± SD (n = 3). (B) Virus replication assay. Clone M-3 cells were infected with each virus at an MOI of 0.1 and incubated for 24 or 48 h. Virus yields were measured using a plaque assay on Vero cells. The dotted line indicates the input inoculum at the time of infection (4 × 104 pfu). The results are presented as the mean ± SD (n = 3). (C) ELISA for murine IL-12. Clone M-3 and Vero cells were infected with T-mfIL12, T-01, or mock at an MOI of 2 and incubated for 18 h. Supernatants were collected and IL-12 concentrations were determined by ELISA. The results are presented as the mean ± SD (n = 3). ND, not detected. (D) Anti-tumor efficacy in immunocompetent mice. DBA/2 mice bearing bilateral subcutaneous Clone M-3 tumors (T-mfIL12, n = 8; T-01, n = 7; mock, n = 13) were treated by intratumoral injections with each virus (4 × 104 pfu) into the left-side tumor on days 0 and 3. Tumor volume was monitored twice weekly. Left and right parts of the image show tumor growth at the treated (injected) and contralateral sites, respectively. The results are presented as the mean ± SEM. (E) Anti-tumor efficacy in immunodeficient mice. Athymic mice bearing bilateral subcutaneous Clone M-3 tumors (T-mfIL12, n = 9; T-01, n = 8; mock, n = 10) were treated as in (D). Left and right parts of the image show tumor growth at the treated (injected) and contralateral sites, respectively. The results are presented as the mean ± SEM. (F) ELISpot assay for systemic immune responses. DBA/2 mice bearing unilateral Clone M-3 tumors were treated with T-mfIL12, T-01 (4 × 104 pfu), or mock on days 0 and 3. On day 14, spleens were harvested, and IFN-γ and IL-4 ELISpot assays were performed after Clone M-3 stimulation. The results are presented as the mean ± SD (n = 3). ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; n.s., not significant. In bilateral subcutaneous tumor models, T-mfIL12 was injected into the left tumors only. The dose (4 × 104 pfu) used was selected based on a dose-response study with the control virus T-01 in a unilateral subcutaneous tumor model (Figure S2A). Compared with T-01, T-mfIL12 significantly suppressed the tumor growth on both the treated and contralateral sides (p < 0.0001 and p = 0.0022, respectively; Figure 1D). At a higher dose (2 × 105 pfu), complete responses were observed in 3/8 mice in a separate experiment using the bilateral subcutaneous Clone M-3 model (Figure S2B). In athymic mice, T-mfIL12 retained its antitumor effects on the treated side compared with T-01 (p = 0.0108; Figure 1E), but failed to suppress contralateral tumors, suggesting that the effect on non-infected remote tumors requires T cell-mediated immunity. Despite comparable in vitro cytotoxicity, T-mfIL12 showed superior in vivo efficacy relative to T-01, likely reflecting IL-12-driven activation of antitumor immune responses. These results highlight the therapeutic advantage of combining virus-mediated oncolytic activities with immune modulation via IL-12 expression. T-mfIL12 enhances the tumor-reactive immune response To further evaluate the ability of T-mfIL12 to enhance systemic tumor-specific immunity, we performed an enzyme-linked immunosorbent spot (ELISpot) assay to assess Clone M-3-stimulated IFN-γ secretion by splenocytes on day 14 post-treatment (Figure 1F). Compared with the T-01 group, mice treated with T-mfIL12 exhibited a significant increase in the number of Clone M-3-stimulated IFN-γ-secreting splenocytes (p < 0.0001), while the number of IL-4-secreting splenocytes remained unchanged (p = 1.0000). These findings indicate that T-mfIL12 augments the antitumor efficacy of oncolytic HSV-1 by eliciting a robust tumor cell-reactive T cell response. T-mfIL12 induces systemic antitumor immune responses To elucidate the mechanisms underlying the local and systemic antitumor effects of T-mfIL12, we analyzed the temporal dynamics of immune-related gene expression in tumor tissues following treatment (Figures 2 and S3). In the virus-injected tumors, Il12a and Il12b were markedly upregulated as early as day 0, confirming robust IL-12 expression. In addition, genes involved in effector function (Ifng, Gzmb, and Prf1), chemotaxis (Ccl5, Cxcl10, and Cxcl11), inflammation, and cell death (Tnf, Il1a, Il1b, Fasl, Fas, Cd40, Cd8a, and Nos2) were strongly induced in the T-mfIL12 group. Although some of these genes showed transient upregulation on day 1 in the T-01 group, their expression declined rapidly thereafter. By contrast, the T-mfIL12 group sustained elevated expression through days 3–7, indicating prolonged immune activation. Notably, T-mfIL12 also induced the expression of immune checkpoint-related genes, including Ctla4 (CTLA-4), Icos, Pdcd1 (PD-1), and Cd274 (PD-L1) in the treated tumors. Importantly, elevated expression of key immune mediators, such as Ifng (IFN-γ), Gzmb, Prf1, Cxcl11, Il1a, Nos2, Il21, and Pdcd1 (PD-1) was also observed in contralateral non-injected tumors on day 7, suggesting that T-mfIL12 elicits a systemic antitumor immune response extending beyond the site of injection. Supporting this, quantitative PCR (qPCR) analysis of viral genomic DNA confirmed minimal spread to contralateral tumors, indicating that the observed effects on non-infected remote tumors were mediated by immune activation and not by viral dissemination (Figure S4). Immune-related gene expression profiles in tumors following T-mfIL12 treatment Gene expression levels of representative immune-related genes were analyzed in both virus-injected and contralateral non-injected tumors from DBA/2 mice bearing bilateral subcutaneous Clone M-3 tumors. When tumors reached 5–6 mm in diameter, either T-mfIL12 or T-01 (4 × 104 pfu) was administered intratumorally into the left-side tumors on day 0. Tumors were harvested on days 0, 1, 3, and 7 post-injection (n = 3 per group per time point). The mock-treated group on day 0 (n = 5) was used as the biological reference baseline. Total RNA was extracted and analyzed using the TaqMan Array Mouse Immune Panel and custom TaqMan Array 96-Well FAST Plates. Gene expression levels were normalized to those of multiple endogenous control genes (Actb, Gapdh, Gusb, and Hprt), and results were expressed as log2-fold changes relative to the average value of the contralateral tumors in the mock group on day 0. Dot plots show temporal expression changes of selected immune-related genes, including cytokines, chemokines, cytotoxic mediators, and immune checkpoint molecules, along with median bars. Genes were selected from the full dataset (see Figure S3) based on biological relevance and dynamic expression profiles. Efficacy of T-mfIL12 in combination with systemic PD-1 blockade One of the standard initial treatments for patients with unresectable progressive malignant melanoma is the systemic administrations of ICIs including anti-PD-1 antibodies. To assess whether the antitumor activity of T-mfIL12 could be augmented by immune checkpoint inhibition, we treated DBA/2 mice bearing bilateral subcutaneous Clone M-3 tumors with intratumoral T-mfIL12 alone or in combination with systemic administration of an anti-PD-1 antibody. Tumor growth was monitored on both the treated and contralateral sides (Figure 3). The combination of T-mfIL12 and anti-PD-1 antibody significantly enhanced the antitumor efficacy compared with T-mfIL12 alone on the untreated contralateral side (p < 0.0001), whereas, on the treated side, a relatively high efficacy was shown by T-mfIL12 alone, resulting in a tendency for (but not significant) enhancement by the combination (p = 0.057). The combination also enhanced the antitumor efficacy compared with anti-PD-1 antibody alone on both sides (p < 0.0001 for both). Because the treatment effect on the injected side was most apparent in the proportion of mice achieving marked tumor control, we performed a responder analysis based on the number of mice with tumor volumes ≤400 mm3 at the time point of maximal separation using Fisher’s exact test: T-mfIL12 combined with anti-PD-1 significantly increased the responder rate compared with T-mfIL12 alone on both sides (p = 0.0498 on day 37 for treated side and p = 0.0152 on day 31 for contralateral side). The combination of T-01 and anti-PD-1 showed a significantly greater tumor suppression when compared with T-01 alone (p = 0.0003 for treated side and p = 0.0107 for contralateral side) or when compared with anti-PD-1 antibody alone (p < 0.0001 for both sides). In addition, complete responses (≤50 mm3 in both tumors) were observed in 1/8 mice in the T-01 + anti-PD-1 group and 3/8 mice in the T-mfIL12 + anti-PD-1 group at day 44. The results indicate that systemic PD-1 blockade potentiates the therapeutic efficacy of the G47Δ-based oncolytic HSV-1. Combination efficacy of T-mfIL12 and anti-PD-1 antibody in bilateral tumor models DBA/2 mice bearing bilateral subcutaneous Clone M-3 tumors were treated by intratumoral injection of T-mfIL12, T-01 (4 × 104 pfu), or mock into the left-side tumors on days 0 and 3, after tumors had reached a diameter of 5–6 mm. Anti-PD-1 antibody or the isotype control (200 μg) was administered intraperitoneally on days 0, 3, and 6. Tumor growth in both treated and contralateral tumors was evaluated by measuring the tumor size twice weekly. The results are presented as the mean ± SEM (mock + isotype control, n = 8; mock + anti-PD-1 antibody, n = 10; T-01 + isotype control, n = 10; T-01 + anti-PD-1 antibody, n = 8; T-mfIL12 + isotype control, n = 9; T-mfIL12 + anti-PD-1 antibody, n = 8). ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001. Preclinical safety studies of single and repeated intradermal administrations with T-mfIL12 and T-hIL12 To initiate clinical trials for malignant melanoma, we conducted preclinical safety studies of T-hIL12, a human IL-12-expressing oncolytic HSV-1, along with T-mfIL12, using HSV-1-sensitive A/J mice.22 Mice received either a single intradermal injection (low dose: 5 × 105 pfu; high dose: 5 × 106 pfu) or repeated administrations (four times per week), and were monitored for 17 and 32 days, respectively. Throughout the observation period, general health status (Table S1)8 and body weight were assessed, followed by histopathological examination of the major organs. Neither single nor repeated administrations of T-mfIL12 or T-hIL12 resulted in clinical abnormalities or significant weight loss (Figures 4A, 4B, 4D, and 4E). Histopathological analyses revealed mild inflammatory responses at the injection sites in both virus- and mock-treated mice (Figures 4C and 4F), irrespective of the virus type or dose. Histological examination of other major organs revealed no notable abnormalities attributable to virus administration; minor changes were occasionally observed that were also present in mock-treated mice (Tables S2 and S3), indicating that these changes were not virus-related. Overall results support the safety of repeated intradermal administrations of IL-12-expressing oncolytic HSV-1. Preclinical safety assessment of single and repeated intradermal administration of T-mfIL12 and T-hIL12 (A–C) Single intradermal administration. A/J mice received a single intradermal injection of T-mfIL12 or T-hIL12 at low (5 × 105 pfu) or high (5 × 106 pfu) doses, or mock (n = 5 per sex; n = 10 in total per group). (A) Clinical signs were monitored daily and scored based on appearance, spontaneous activity, and response to external stimuli according to the scoring criteria (Table S1). (B) Body weights were measured twice weekly throughout the observation period. (C) Representative histopathological images of the injection site skin collected on day 17 post-administration. Skin tissues were fixed in formalin, embedded in paraffin, sectioned, and stained with hematoxylin and eosin (HE). Scale bars, 100 μm. (D–F). Repeated intradermal administration. A/J mice received repeated intradermal injections (four times per week) of T-mfIL12 or T-hIL12 at low (5 × 105 pfu) or high (5 × 106 pfu) doses, or mock (n = 5 per sex; n = 10 in total per group). (D) Clinical scores were monitored daily using the same composite scoring system evaluating appearance, spontaneous activity, and response to external stimuli (Table S1). (E) Body weights were measured twice weekly throughout the study period. (F) Histopathological analysis of the injection site skin on day 11 after the final administration (day 32 from the first dose). Skin tissues were fixed in formalin, paraffin embedded, sectioned, and stained with HE. Representative images from each group are shown. Scale bars, 100 μm. Biodistribution following intradermal administration with T-hIL12 To assess the systemic distribution of T-hIL12 following local administration, we evaluated the biodistribution of viral DNA in major organs using qPCR based on the droplet digital PCR (ddPCR) system. Mice received a single intradermal injection of 5 × 106 pfu of T-hIL12, and tissues were collected at 24 and 48 h post-administration. HSV-1 genomic DNA was then extracted and quantified. Viral DNA was detected exclusively at the injection site at both points and was undetectable in other major organs, including the brain, lung, liver, kidney, and blood (Table 1). These findings indicate that T-hIL12 does not disseminate systemically after intradermal injection, supporting its safety. Table 1Biodistribution of T-hIL12 after intradermal administrationPost-injectionTreatment groupsNo.Skin (injection site)Skin (non-injection site)BrainLungHeartLiverKidneyMuscleTestis/OvaryBlood24 hmock♂1000000007.802000000001.50♀31.300000002.304000000002.70T-hIL12♂52000000000003.5001.406200000000.70000.7001.50.876300001.200000.71.30♀82000000000000000092000000002.80.700.7000.701033000.700.7001.5048 hmock♂1100000.70003.01.012000000.8000.80♀1300000.8000001400000000.70.80T-hIL12♂15200000002.10003.46.91.31.4016200000000000.701.300.701717390.7001.403.91.500♀18157200000.6007.40001920000000000000000201099000000.707.01.56.30A/J mice were treated by intradermal administration of T-hIL12 (high dose: 5 × 106 pfu; n = 3 per time point for each sex; n = 6 in total) or mock (n = 2 per time point for each sex; n = 4 in total). At 24 h and 48 h post-injection, major organs and whole blood were harvested and frozen for analysis. Viral DNA was extracted and quantified using ddPCR with a probe targeting the HSV-1 DNA polymerase gene. G47Δ genomic DNA was included as a positive control, with 10˗5 ng of G47Δ genomic DNA corresponding to 100 copies. Results were expressed as copy numbers. Only those samples with ≥10 copies were judged positive. Samples with <10 copies were judged negative (not detected). The upper detection limit of the ddPCR assay was 2.0 × 107 copies. Viral DNA was detected only at the injection site (skin) at both 24 and 48 h. Biodistribution of T-hIL12 after intradermal administration A/J mice were treated by intradermal administration of T-hIL12 (high dose: 5 × 106 pfu; n = 3 per time point for each sex; n = 6 in total) or mock (n = 2 per time point for each sex; n = 4 in total). At 24 h and 48 h post-injection, major organs and whole blood were harvested and frozen for analysis. Viral DNA was extracted and quantified using ddPCR with a probe targeting the HSV-1 DNA polymerase gene. G47Δ genomic DNA was included as a positive control, with 10˗5 ng of G47Δ genomic DNA corresponding to 100 copies. Results were expressed as copy numbers. Only those samples with ≥10 copies were judged positive. Samples with <10 copies were judged negative (not detected). The upper detection limit of the ddPCR assay was 2.0 × 107 copies. Viral DNA was detected only at the injection site (skin) at both 24 and 48 h. Effect of T-mfIL12 intradermal administration on cytokine levels in peripheral blood Because IL-12 is species specific, T-mfIL12 expressing murine IL-12 was used to evaluate cytokine responses following intradermal administration in mice. We quantified 23 cytokines in peripheral blood using the BioPlex mouse cytokine panel at pre-treatment and at 1, 6, 24, and 48 h after a single intradermal injection with 5 × 106 pfu of T-mfIL12. An increase in granulocyte colony-stimulating factor (G-CSF), keratinocyte-derived chemokine (KC), and RANTES levels was observed at 6 h post-administration, while the levels of IL-9, IL-1β, and eotaxin decreased at 1, 24, and 48 h, respectively (Figure 5). These changes were generally transient and varied among individual animals. Notably, no marked alterations were detected in most other cytokines. As the experiment was conducted under non-tumor conditions, the IL-12 expression was likely limited owing to the tumor-selective replication of G47Δ-based oncolytic HSV-1. Chronological quantification of cytokines in peripheral blood A/J mice were treated by intradermal administration of T-mfIL12 (5 × 106 pfu). Serum samples were collected before treatment (pre-administration) and at 1, 6, 24, and 48 h post-administration (n = 3 per time point for each sex; n = 6 in total). Cytokine concentrations were quantified using the Bio-Plex Pro Mouse Cytokine GI 23-Plex Panel. Boxplots represent serum cytokine levels for 23 analytes, centered on the median, with individual values overlaid. Asterisks indicate statistical significance compared with pre-treatment levels. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001. pre, pre-administration. Toxicity studies with intracerebral administrations The brain is the most sensitive organ for detecting HSV-1 toxicity,21 so intracerebral injections in A/J mice are standardly used to test the safety of newly developed oncolytic HSV-1. Whereas T-hIL12 is the virus to be used in clinical trials, because human IL-12 does not function in mice, both T-mfIL12 and T-hIL12 were used in the safety studies. Either virus (low dose: 2 × 106 pfu; high dose: 5 × 106 pfu) or wild-type HSV-1 (strain F; 2 × 103 pfu), a positive control, was injected into the brain of A/J mice. Wild-type HSV-1 caused 100% mortality by day 14. By contrast, mice that received T-mfIL12 or T-hIL12 survived for over eight weeks without exhibiting any clinical symptoms even at the dose of 5 × 106 pfu, 2,500-fold higher than that of the wild-type HSV-1 (Figures 6A and 6B). One mouse in the T-mfIL12 group died on day 4 post-injection, likely due to a procedural cause during administration. Macroscopic examination revealed discolored abnormal brains compatible with severe encephalitis in all mice treated with wild-type HSV-1, with 6 of 10 mice showing hemorrhage on the brain surface, whereas none of the brains showed abnormal appearance in mice treated with either T-mfIL12 or T-hIL12 (Figure 6C). G47Δ-based IL-12-expressing oncolytic HSV-1 proved highly safe in these evaluation models. The intracerebral safety results strongly support the clinical translation of T-hIL12. Toxicity studies following intracranial administration A/J mice were treated by intracranial administration of T-mfIL12, T-hIL12 (low dose: 2 × 106 pfu; high dose: 5 × 106 pfu), wild-type HSV-1 (strain F; 2 × 103 pfu), or mock (n = 10). (A) Clinical observations were scored daily for weeks 1–3, and then twice weekly until week 8 using a composite scoring system assessing appearance, spontaneous activity, and response to external stimuli (Table S1). (B) Body weight was measured twice weekly. (C) Representative macroscopic examination of whole brains collected on day 56 post-injection, or earlier if animals died. Brains were fixed in formalin and photographed to allow visual comparison of gross morphology. h, brains with hemorrhage. Scale bars, 1 cm. Systemic tolerability and serum cytokine/chemokine dynamics in tumor-bearing mice Building on the safety studies, we next assessed systemic tolerability and serum cytokine/chemokine dynamics under tumor-bearing conditions using a DBA/2 unilateral subcutaneous Clone M-3 model. After tumors reached 5–6 mm in diameter, mice received a single intratumoral injection of T-mfIL12, T-01 (4 × 104 pfu), or mock on day 0, and body weight and serum cytokines/chemokines were monitored over time (n = 4–5 per group). All groups showed a mild early decrease in body weight consistent with anesthesia/phlebotomy, with no evidence of treatment-related weight loss (Figure 7A). One mouse each in the mock and T-01 groups exhibited late weight loss coincident with tumor enlargement. Systemic tolerability and serum kinetics of key cytokines/chemokines in tumor-bearing mice treated with T-mfIL12 (A) DBA/2 mice bearing unilateral subcutaneous Clone M-3 tumors were treated by intratumoral injection of T-mfIL12, T-01 (4 × 104 pfu), or mock on day 0, after tumors had reached a diameter of 5–6 mm (mock, n = 4; T-01, n = 5; T-mfIL12, n = 5). Body weight time courses normalized to each mouse’s day 0 value (%) are shown as individual mouse traces. (B) Serum cytokine/chemokine concentrations were quantified using the Bio-Plex Pro™ Mouse Chemokine Panel 31-Plex and IL-12(p70)/IL-12(p40) (single-analyte assays) were assayed separately using aliquots from the same serum samples on a Bio-Plex 200 system. Representative cytokines/chemokines are shown (mock, n = 4; T-01, n = 4; T-mfIL12, n = 5): One T-01 mouse was not included due to insufficient amount of serum. Results are expressed as log2 fold-change relative to each mouse’s pre-administration (day 0) value and presented as the mean ± SEM. For IL-12(p70) only, out-of-range (below) values are imputed at LOD/2 (LOD defined as the smallest positive concentration on the plate). The remaining analytes from the 31-plex panel are provided in Figure S5. The time course of serum cytokines/chemokines are summarized as log2 fold-change relative to each mouse’s pre-treatment value in Figures 7B and S5. IL-12(p70) in the T-mfIL12 group showed a transient increase peaking on day 2 (range, 30–193 pg/mL) followed by a rapid decline, whereas IL-12(p40) rose modestly but less prominently (Figure S6). Intratumoral T-mfIL12 caused early and transient rises of CCL7 and CCL12 levels, coinciding with the serum IL-12(p70) elevation, suggestive of CCR2-axis recruitment. On the other hand, Th1-related (CXCL10/CXCL11, IL-2), inflammatory (TNFα, IL-1β, IL-6, and GM-CSF), and regulatory (IL-10 and CCL22) mediators were minimally affected by intratumoral T-mfIL12, with serum levels comparable to or slightly lower than mock and T-01. The results indicate that intratumoral T-mfIL12 injection causes a transient increase in the serum IL-12 level, with limited effects on the systemic cytokine/chemokine profiles, supporting the safe features of G47Δ-based IL-12 expressing oncolytic HSV-1. Discussion Besides malignant glioma, approved for marketing, G47Δ has been clinically tested for prostate cancer (UMIN000010463, jRCTs033210603), olfactory neuroblastoma (UMIN000011636, jRCTs033180325), and malignant pleural mesothelioma (UMIN000034063, jRCTs033180326). These efforts reflect growing interest in the use of oncolytic HSV-1 as a broadly applicable immunotherapeutic platform. In this study, we show that G47Δ exhibits potent antitumor activity against malignant melanoma both in vitro and in vivo. The results are consistent with previous reports demonstrating the efficacy of HSV1716 and JS-1/34.5, both γ34.5-deleted HSV-1 strains, in melanoma models.23,24 Notably, the clinical success of T-VEC in melanoma highlights the translational relevance of recombinant HSV-1.25 We further explored the therapeutic potential of T-mfIL12, a murine IL-12-expressing derivative of G47Δ. A key advance over previously reported IL-12-expressing oncolytic HSV-1 constructs is that our approach utilizes the clinically validated triple-mutated G47Δ as the backbone and evaluates both murine and human fusion-type IL-12-expressing viruses, thereby bridging mechanistic efficacy with translational safety. Although T-mfIL12 retained cytopathic and replicative properties similar to those of G47Δ and T-01 in vitro, it demonstrated superior in vivo efficacy not only in injected tumors but also in non-injected remote tumors. Quantitative PCR confirmed that viral DNA remained localized in the injected tumor, consistent with HSV-1’s nature of not circulating in the blood, suggesting that the systemic antitumor effects were immune mediated. Further, abolishment of efficacy in contralateral tumors indicates that T cells are required for remote effects. Nevertheless, T-mfIL12 was more efficacious than T-01 even in immunodeficient hosts, indicating the contribution of innate responses including NK cell-mediated immunity. Immune-related gene expression profiling revealed that T-mfIL12 triggered sustained expressions of effector molecules (Ifng, Gzmb, and Prf1), inflammatory cytokines (Il1a, Il1b, and Tnf), chemokines (Cxcl10, Cxcl11, and Ccl5), and immune checkpoint molecules (Ctla4, Icos, and Pdcd1). By contrast, T-01 only induced transient activation. Importantly, immune checkpoint genes such as Pdcd1 (PD-1), Ctla4 (CTLA-4), and Tigit (TIGIT) were also upregulated in contralateral tumors, suggesting that T-mfIL12 induces systemic T cell activation accompanied by compensatory regulatory mechanisms. These findings are consistent with prior reports on IL-12-expressing oncolytic HSV-1,16,26,27 and highlight their potential to stimulate robust immunity while avoiding systemic toxicity. The upregulation of multiple checkpoint molecules by T-mfIL12 provides a rationale for the combination therapy with ICIs. Indeed, co-administration of intratumoral T-mfIL12 with systemic anti-PD-1 antibody led to significantly enhanced tumor suppression compared with either monotherapy, consistent with previous reports demonstrating synergistic effects between oncolytic viruses and ICIs.28 Incorporating co-stimulatory molecules, such as OX40L, has shown promise in preclinical studies.29 Arming oncolytic HSV-1 with a variety of immunomodulatory genes is a viable strategy to intensify antitumor immunity. Clinical studies have shown that T-VEC improves outcomes in advanced melanoma, both as monotherapy and in combination with ipilimumab.30 The phase 3 MASTERKEY-265 trial, however, failed to show additional benefits when T-VEC was combined with pembrolizumab.31 T-VEC as well as G47Δ and T-hIL12 are administered by intratumoral injections. In our experience, to bring out full efficacy, it is important to inject the virus precisely into the tumor, so that most of the virus infects the tumor cells and a robust viral replication occurs, accompanying vast tumor cell destruction. It remains unknown whether the outcome would have been different, if the trial was performed in limited number of institutions and by physicians skilled in intratumoral injections. Because of the species specificity of IL-12, for clinical translation, we conducted comprehensive safety studies using both murine (T-mfIL12) and human (T-hIL12) IL-12-expressing oncolytic HSV-1 in HSV-1-sensitive A/J mice. Both viruses were shown safe by single and repeated intradermal administrations, and the viral DNA remained confined to the injection site with systemic cytokine perturbations being minimal. An increase in G-CSF, KC, and RANTES levels at 6 h was transient and self-limited, unlikely to have a clinical implication. These findings are particularly meaningful considering the historical systemic toxicity of IL-12,11,12 reinforcing the safety advantages of local IL-12 delivery via oncolytic HSV-1. Furthermore, the lack of toxicity following intracerebral inoculation with T-mfIL12 or T-hIL12, in stark contrast to the 100% mortality induced by wild-type HSV-1 at a 1/2,500 dose, reinforces the non-pathogenic nature of the G47Δ backbone. The parallel use of viruses armed with species-matched and human transgene may become a practical precedent of preclinical safety tests for developing cytokine-expressing oncolytic viruses. Recent report with vPD1/IL-12, an oncolytic myxoma virus encoding IL-12 together with a soluble PD-1 module, revealed systemic toxicities emerging several days after intratumoral dosing in tumor-bearing mice.32 By contrast, intratumoral injections with T-mfIL12 caused neither treatment-related weight loss nor sustained systemic cytokine/chemokine elevations, suggesting that a local IL-12 expression using HSV-1 of the G47Δ backbone can stimulate antitumor immunity without prolonged systemic toxicity. Backed by the present safety studies and the safety of G47Δ that has been proven clinically,9,10 a physician-initiated clinical trial of T-hIL12 is currently underway in Japan (jRCT2033190086). Based further on the present study, the ongoing phase 2 trial in patients with stage III/IV malignant melanoma is designed to assess whether upfront repeated doses of intratumoral T-hIL12, added on the initial treatment with systemic PD-1 blockade by nivolumab (Opdivo), improve the efficacy compared with nivolumab alone. The clinical advancement of T-hIL12 leads to a broad potential of rationally designed oncolytic HSV-1 armed with immunomodulatory molecules as next-generation immunotherapeutic platforms. Materials and methods Cell lines Vero (African green monkey kidney) and Clone M-3 (a melanoma cell line derived from DBA/2 mice) were purchased from the American Type Culture Collection (Manassas, VA, USA). The human melanoma cell lines A2058 and Mewo were obtained from the Japanese Collection of Research Bioresources (Osaka, Japan), and melanoma cell lines 624, 888, and 938 were kindly provided by J. Wunderlich (National Institutes of Health, Bethesda, MD, USA). Vero, A2058, and Mewo cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM; Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS; Thermo Fisher Scientific). Melanoma 624, 888, and 938 cells were maintained in DMEM supplemented with 10% FBS and 2 mM L-glutamine (Merck, Darmstadt, Germany). Clone M-3 cells were maintained in Ham’s F-12K medium (FUJIFILM Wako Pure Chemical Corp., Osaka, Japan) supplemented with 15% horse serum (Thermo Fisher Scientific) and 2.5% FBS. All cell lines were cultured at 37°C in a humidified atmosphere containing 5% CO2. Viruses G47Δ, a triple-mutated conditionally replicating oncolytic HSV-1, was generated as previously described.8 T-mfIL12, an IL-12-expressing derivative of G47Δ, was engineered using the T-BAC system by inserting a murine IL-12 fusion gene (p35-p40) into the ICP6-deletion site.21 T-hIL12 was constructed using the G47Δ backbone by inserting the human IL-12 fusion gene (p35-p40) using the same approach. T-01 is an unarmed control virus for T-mfIL12. The mock control was prepared from the virus suspension buffer-infected cells following the same procedures as those used for virus inoculation. In vitro cytotoxicity assay For the in vitro cytotoxicity assay, each cell line was seeded in 6-well plates at a density of 2 × 105 cells/well and incubated overnight at 37°C in 5% CO2. Cells were then infected with G47Δ, T-01, or T-mfIL12 at an MOI of 0.01, 0.1, or 1, and further incubated in medium containing 1% heat-inactivated FBS. Cell viability was assessed daily for four days using a Coulter counter (Beckman Coulter, Pasadena, CA, USA). Results were expressed as the percentage of viable cells relative to the mock-infected controls. Each condition was assessed in triplicate wells (technical replicates), with separate wells used for each time point. Virus replication assay Clone M-3 cells were seeded in 6-well plates at a density of 4 × 105 cells/well and infected with G47Δ, T-01, or T-mfIL12 at an MOI of 0.1. Each condition was assayed in triplicate wells (technical replicates). After incubation at 37°C for 24 or 48 h, cells were harvested and lysed by freeze-thaw cycles. Viral titers were determined by a plaque assay using Vero cells. ELISA for the detection of mouse IL-12 expression Vero and Clone M-3 cells were plated in 24-well plates at a density of 1 × 105 cells/well and cultured overnight at 37°C in 5% CO2. Cells were then infected with T-01 or T-mfIL12 at an MOI of 2 and further incubated in growth medium containing 1% heat-inactivated FBS for 18 h. Culture supernatants were collected, and IL-12 p70 levels were quantified using a Quantikine ELISA mouse IL-12 p70 immunoassay (R&D Systems, Minneapolis, MN, USA), according to the manufacturer’s instructions. Each condition was measured in triplicate wells (technical replicates). Animal studies DBA/2 mice (5-week-old females), BALB/c nu/nu mice (5-week-old females), and A/J mice (5-week-old males and females) were purchased from Japan SLC (Shizuoka, Japan). All animal experiments were approved by the Ethics Committee for Animal Experimentation of the University of Tokyo. The mice were housed under specific-pathogen-free conditions (temperature: 20°C–23°C, humidity: 40%–60%, light cycle: 12 h light/12 h dark). Mice were fed a standard diet and provided with water ad libitum for one week prior to the start of the study. Subcutaneous tumor models A2058 or Mewo cells (2 × 106) were injected subcutaneously into the left flank of 6-week-old BALB/c nu/nu mice. When tumors reached a diameter of 5–6 mm, mice received intratumoral injections with G47Δ (2 × 105 pfu) or mock on days 0 and 3. For the bilateral models, Clone M-3 cells (1 × 106) were injected into both flanks of syngeneic 6-week-old DBA/2 or athymic BALB/c nu/nu mice. T-mfIL12, T-01 (4 × 104 pfu), or mock was administered intratumorally into the left-side tumor on days 0 and 3. In the combination therapy experiments, anti-PD-1 antibody (200 μg, clone RMP1-14; BioXCell, West Lebanon, NH, USA) or isotype control (rat IgG2a, clone 2A3) was administered intraperitoneally on days 0, 3, and 6. Tumor volume was measured twice a week and calculated using the following formula: volume (mm3) = length × width × height × 0.52. Mice were euthanized when tumors reached 20 mm in diameter in the bilateral models and 24 mm in diameter in the unilateral models, as approved by the Ethics Committee for Animal Experimentation of the University of Tokyo. Real-time qPCR and gene expression analysis Clone M-3 cells (1 × 106) were implanted subcutaneously into the bilateral flanks of 6-week-old DBA/2 mice. When tumors reached a diameter of 5–6 mm, T-mfIL12, T-01 (4 × 104 pfu), or mock was intratumorally injected into the left-side tumor (treated side, T) on day 0. Tumors were harvested on days 0, 1, 3, and 7 and snap-frozen in liquid nitrogen (n = 3 per time point). For normalization, five tumors from mock-treated mice on day 0 were used (n = 5). Total RNA and genomic DNA were simultaneously extracted from the same tissue samples using the RNeasy Plus Mini Kit (QIAGEN, Hilden, Germany). Genomic DNA was extracted from the gDNA Eliminator spin column using the QIAamp DNA Mini Kit (QIAGEN) following the manufacturer’s protocol. To quantify viral genomic DNA, qPCR targeting HSV-1 DNA polymerase was performed using the 7500 Fast Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) with the TaqMan Fast Universal PCR Master Mix (2×). The primers and probe used were as follows: forward primer: 5′-GGCACGCGGCAGTACTTT-3′, reverse primer: 5′-CCATGCGCTCGCAGAGA-3′, probe: 5′-AGGTCGACAGGCACCTACAATGCCG-3′. A plasmid containing the target sequence was used to generate a standard curve for quantification. Copy numbers ≥10 were considered detectable. For gene expression analysis, cDNA was synthesized using the ReverTra Ace qPCR RT Master Mix with gDNA Remover (Toyobo, Osaka, Japan). Quantitative PCR was performed using the TaqMan Array Mouse Immune Panel and custom-designed TaqMan Array 96-Well FAST Plates with Fast Advanced Master Mix (Thermo Fisher Scientific) on a QuantStudio 7 Flex Real-Time PCR System (Applied Biosystems). Expression data were analyzed using ExpressionSuite Software v.1.3 (Applied Biosystems). The Actb, Gapdh, Gusb, and Hprt genes were included in the analysis as endogenous controls. Results were expressed as log2-fold changes relative to the average value of the untreated (N) mock group at day 0. ELISpot assay Clone M-3 cells (1 × 106) were implanted subcutaneously into the left flank of 6-week-old DBA/2 mice. When tumors reached a diameter of 5–6 mm, mice received intratumoral injections of T-01, T-mfIL12 (4 × 104 pfu), or mock on days 0 and 3. On day 14, spleens were harvested and single-cell suspensions of splenocytes were prepared. Red blood cells were lysed using RBC lysis buffer (eBioscience, Santa Clara, CA, USA), according to the manufacturer’s protocol. To assess tumor-specific immune responses, splenocytes were co-cultured with Clone M-3 cells, and IFN-γ or IL-4 secretion was quantified using ELISpotPLUS kits for Mouse IFN-γ and Mouse IL-4 (MABTECH, Nacka Strand, Sweden), following the manufacturer’s protocols. Spot enumeration and analysis were conducted by ZellNet Consulting, Inc. (Fort Lee, NJ, USA). Splenocytes from individual mice (n = 3 mice per group; biological replicates) were analyzed without pooling, and each condition was plated in triplicate wells (technical replicates). Safety study of intradermal administration in mice 6-week-old A/J mice were treated with either a single or repeated (four times per week) intradermal administration of T-mfIL12, T-hIL12 (low dose: 5 × 105 pfu; high dose: 5 × 106 pfu), or mock (n = 5 for each sex, n = 10 in total per group). Clinical observations were monitored and scored daily (Table S1),8 and the body weight was measured twice weekly. On day 17 (single administration) or day 11 (repeated administration) after the final treatment, major organs, including skin (both injection and non-injection sites), brain, lung, heart, liver, kidney, muscle, and reproductive organs (testes or ovaries), were collected and fixed in 20% neutral buffered formalin (MUTO PURE CHEMICALS, Tokyo, Japan). Tissue samples were processed into 4-μm paraffin sections and stained with hematoxylin and eosin. The pathological evaluation was conducted by the Central Institute for Experimental Animals (Kawasaki, Japan). Biodistribution 6-week-old A/J mice were treated with an intradermal administration of T-hIL12 (high dose: 5 × 106 pfu; n = 3 per time point for each sex; n = 6 in total) or mock (n = 2 per time point for each sex; n = 4 in total). At 24 and 48 h post-injection, the major organs were harvested, and whole blood was collected and stored at ˗80°C. Viral DNA was isolated using the QIAamp Fast DNA Tissue kit or QIAamp DNA Mini kit (QIAGEN) according to the manufacturer’s instructions. Viral DNA was quantified using ddPCR with the QX200 Droplet Digital PCR System (Bio-Rad, Hercules, CA, USA), employing the same HSV-1 DNA polymerase-specific primer and probe set described in the “real-time qPCR and gene expression analysis” section. ddPCR Supermix for Probes (Bio-Rad) was used for amplification. G47Δ genomic DNA served as a positive control, and quantification standards were prepared using known copy numbers (100 copies = 10˗5 ng). Results were considered positive when the HSV-1 copy number was 10 per reaction or higher. The upper detection limit of the ddPCR assay was 2.0 × 107 copies. Multiplex cytokine analysis 6-week-old A/J mice were treated with an intradermal administration of T-mfIL12 (high dose: 5 × 106 pfu; n = 3 per sex; n = 6 in total). Serum was collected pre-administration and at 1, 6, 24, and 48 h post-administration. Serum cytokine levels were measured using a Bio-Plex Pro mouse cytokine GI 23-Plex panel with the Bio-Plex 200 System (Bio-Rad) according to the manufacturer’s instructions. Serum cytokine/chemokine profiling Clone M-3 cells (1 × 106) were implanted subcutaneously into the left flank of 6-week-old DBA/2 mice. When tumors reached a diameter of 5–6 mm, mice received a single intratumoral injection of T-01, T-mfIL12 (4 × 104 pfu), or mock on day 0 (n = 4–5 per group). Serum was collected pre-administration (day 0) and at 1, 2, 3, 7, and 14 days post-administration. Serum cytokine levels were measured using a Bio-Plex Pro mouse chemokine panel 31-Plex and single-analyte assays for IL-12(p70) and IL-12(p40) on the Bio-Plex 200 System (Bio-Rad) according to the manufacturer’s instructions. Values below the analytical range were reported by the software as out of range (below) and were imputed at one-half of the limit of detection (LOD/2) on a per-analyte basis, where the LOD was defined as the smallest positive concentration observed for that analyte on the plate. Results were expressed as log2-fold change relative to each mouse’s pre-administration (day 0) value. Toxicity study by intracerebral administration 6-week-old female A/J mice were treated with intracerebral administration of T-mfIL12, T-hIL12 (low dose: 2 × 106 pfu; high dose: 5 × 106 pfu), wild-type HSV-1 (strain F; 2 × 103 pfu), or mock (n = 10 per group). Clinical observations were monitored and scored daily for the first three weeks and twice weekly thereafter until week 8. Body weight was measured twice weekly. The brains of mice that died during the follow-up period were removed and fixed in formalin. On day 56 post-administration, the brains of all surviving mice were harvested and fixed in 20% neutral buffered formalin (MUTO PURE CHEMICALS). Statistical analysis Student’s t tests were applied to compare two groups unless described otherwise, whereas one-way ANOVA with Tukey’s post-hoc test was applied for comparisons among three or more groups. For tumor growth analysis, the effects of multiple two-factor levels were compared using repeated-measures two-way ANOVA with Bonferroni’s correction applied to the post hoc test unless specified otherwise. Exact n values and any additional multiple-comparison procedures are specified in the figure legends. Statistical significance was set at p < 0.05. Analyses were performed using Prism 9.0 (GraphPad Software, San Diego, CA, USA) or the TumGrowth online tool (kroemerlab.shinyapps.io/TumGrowth/).33 Data and code availability The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request. Acknowledgments This research was supported in part by Japan Agency for Medical Research and Development (AMED) under grant numbers JP15lm0103002, JP17lm0203004, and JP20lm0203140 to T.T. We thank Dr. Yasushi Ino for his advice regarding planning the experiments and Edanz (https://jp.edanz.com/ac) for a minor editing of the initial draft. Author contributions M.I. contributed to writing – original draft, investigation, methodology, data curation, formal analysis, visualization, and conceptualization. A.H.N. contributed to investigation, methodology, data curation, formal analysis, and visualization. M.T. and H.F. performed investigation. T.T. contributed to conceptualization, supervision, methodology, formal analysis, funding acquisition, and writing – review and editing. Declaration of interests T.T. is a member of the Editorial Board of Molecular Therapy Oncology. M.T. is a member of a division endowed by Denka Company. Footnotes Supplemental information can be found online at https://doi.org/10.1016/j.omton.2026.201334. Supplemental information Document S1. Figures S1–S6 and Tables S1–S3 Document S2. Article plus supplemental information References Associated Data Supplementary Materials Document S1. Figures S1–S6 and Tables S1–S3 Document S2. Article plus supplemental information Data Availability Statement The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.